C9360 HCPCS code: Dermal substitute, native, non-denatured collagen, neonatal bovine origin (surgimend collagen matrix), per 0.5 square centimeters
C9360 is the HCPCS Level II code for dermal substitute, native, non-denatured collagen, neonatal bovine origin (surgimend collagen matrix), per 0.5 square centimeters. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 300 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | D1A — Medical/surgical supplies |
| Added | 2009-07-01 |
| Last action effective | 2014-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 300 | Clinical: Data |
| practitioner claims | 300 | Clinical: Data |
What changed for C9360
- 2009-07-01: C9360 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9360?
C9360 is the HCPCS Level II code for dermal substitute, native, non-denatured collagen, neonatal bovine origin (surgimend collagen matrix), per 0.5 square centimeters. Short descriptor: "Surgimend, neonatal".
Does Medicare cover C9360?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
How many units of C9360 can be billed per day?
300 on outpatient hospital claims; 300 on practitioner claims (NCCI medically unlikely edits).
Related C93 codes
- C9300 — Injection, indigotindisulfonate sodium, 1 mg
- C9301 — Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9302 — Injection, zanidatamab-hrii, 2 mg
- C9303 — Injection, zolbetuximab-clzb, 1 mg
- C9304 — Injection, marstacimab-hncq, 0.5 mg
- C9305 — Injection, nipocalimab-aahu, 3 mg
- C9306 — Injection, telisotuzumab vedotin-tllv, 1 mg
- C9307 — Injection, linvoseltamab-gcpt, 1 mg
- C9308 — Injection, carboplatin (avyxa), 1 mg
- C9309 — Injection, onasemnogene abeparvovec-brve, per treatment
- C9310 — Injection, leucovorin calcium (avyxa), 1 mg
- C9311 — Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9360
- Watch C9360 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9360
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.